Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRG004A in Advanced Pancreatic Cancer
NCT07138846Phase 3Not yet recruiting
- Sponsor
- Lepu Biopharma Co., Ltd.
- Start
- Jan 2027
- Primary completion
- Jun 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 3 trial of MRG004A in pancreatic cancer (PC), sponsored by Lepu Biopharma Co., Ltd.. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
MRG004A
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT07138846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07138846.